{
    "clinical_study": {
        "@rank": "50129", 
        "acronym": "DKP 3M SC", 
        "arm_group": {
            "arm_group_label": "11.25mg", 
            "arm_group_type": "Experimental", 
            "description": "11.25mg, SC on Day 1 and Day 92"
        }, 
        "brief_summary": {
            "textblock": "Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when\n      administered by subcutaneous route."
        }, 
        "brief_title": "Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven locally advanced or metastatic prostate cancer who are suitable\n             for androgen deprivation therapy\n\n          -  Male aged \u226518 years old\n\n          -  Screening testosterone level of >125 ng/dL\n\n          -  Life expectancy of greater than 12 months in the judgement of the     Investigator\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\n          -  Willing to give signed informed consent freely\n\n          -  Able to adhere to the study visit schedule and other protocol requirements.\n\n        Exclusion Criteria:\n\n          -  Prior hormonal therapy for prostate cancer\n\n          -  Prior surgery or radiotherapy of prostate cancer with curative intent unless\n             disease is verified by a rising prostate specific antigen (PSA) concentration on\n             follow up (elevated PSA values on last two tests conducted at least a month apart)\n             and the patient is eligible for androgen deprivation therapy\n\n          -  Presence or history of any other malignancy except for non melanoma skin cancer\n             adequately treated at least 2 years before study entry\n\n          -  Painful local bone lesions or spinal lesions which may lead to compression\n\n          -  History of myocardial infarction, percutaneous coronary intervention, acute coronary\n             syndrome, coronary artery bypass graft, Class III/IV congestive heart failure,\n             cerebrovascular accident, transient ischaemic attack, or limb claudication at rest,\n             within six months prior to start of study treatment and ongoing symptomatic\n             dysrhythmias, unstable angina, uncontrolled hypertension, and untreated atrial or\n             uncontrolled ventricular arrhythmias\n\n          -  Any condition in opinion of the Investigator, including other active or latent\n             infections, medical or psychiatric conditions, or the presence of laboratory\n             abnormalities, which could confound the ability to interpret data from the study,\n             compromises the objective of the study or places the patient at unacceptable risk if\n             he participates in the study\n\n          -  Abnormal haematological, hepatic or renal functions:\n\n               -  Haemoglobin <9 g/dL, absolute neutrophil count \u22641.5 x 10^9/L or platelets \u2264100 x\n                  10^9/L\n\n               -  Serum creatinine \u22651.5 times the upper limit of normal (ULN)\n\n               -  Aspartate aminotransferase or alanine aminotransferase >2.5 times the ULN\n\n          -  Known hypersensitivity to the study treatment, to any of its excipients\n\n          -  Known active use of recreational drug or alcohol dependence in the opinion of the\n             Investigator\n\n          -  Any current use or use within six months prior to start of treatment, of medications\n             which are known to affect the metabolism and/or secretion of androgenic hormones:\n             e.g. ketoconazole, aminoglutethimide, oestrogens, and progesterone\n\n          -  Use of systemic corticosteroids (inhaled corticosteroids and topical application of\n             corticosteroids are permitted)\n\n          -  Aged \u226590 years for the main study and \u226580 years for those included in the\n             pharmacokinetic (PK) patient population\n\n          -  Participation in any other study or receipt of any investigational compound in the 30\n             days (or five times the elimination half life if this is longer) prior to study entry\n\n          -  Any skin or other condition that may preclude s.c. injection administration\n\n          -  Known brain or epidural metastases."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715129", 
            "org_study_id": "8-55-52014-200"
        }, 
        "intervention": {
            "arm_group_label": "11.25mg", 
            "intervention_name": "Triptorelin Pamoate 11.25mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pleven", 
                        "country": "Bulgaria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shumen", 
                        "country": "Bulgaria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suresnes", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daugavpils", 
                        "country": "Latvia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kutno", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Craiova", 
                        "country": "Romania"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "France", 
                "Latvia", 
                "Poland", 
                "Romania"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer", 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Medical Director, Uro-Oncology", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de Surveillance du Medicament (ANSM)", 
                "Latvia: State Agency of Medicines", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Bulgaria: Bulgarian Drug Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients castrated at Day 29 and proportion of patients with castration maintained at Day 183.", 
            "measure": "The proportion of patients demonstrating castration", 
            "safety_issue": "No", 
            "time_frame": "Days 29 and 183"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715129"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of patients demonstrating castration at Day 92 (before administration of the second dose)and at Day 95 (3-4 days after administration of the second dose)", 
                "measure": "The proportion of patients demonstrating castration", 
                "safety_issue": "No", 
                "time_frame": "Days 92 and 95"
            }, 
            {
                "measure": "Determination of the time to castration (Tcast)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and castration achievement."
            }, 
            {
                "measure": "Plasma triptorelin levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Days 92 and 183"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}